<DOC>
	<DOCNO>NCT02750280</DOCNO>
	<brief_summary>This ia prospective control longitudinal study evaluate effect MatriStem® plus standard local wound care versus standard local wound care alone treatment diabetic foot ulcer ( DFUs ) , assess incidence complete wound heal 16 week ulcer recurrence 2 year follow-up .</brief_summary>
	<brief_title>A Longitudinal Study Evaluate Extracellular Matrix ( MatriStem® ) Treatment Diabetic Foot Ulcers</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Diabetic Foot</mesh_term>
	<mesh_term>Foot Ulcer</mesh_term>
	<criteria>1 . Male female subject 1885 year age diabetes mellitus ( type 1 type 2 ) 2 . Subject 's foot ulcer plantar surface foot . 3 . DFU heal than2 month SOC treatment administer 4 . Subject 's ulcer must Wagner type 1 2 ( uninfected , extend dermis subcutaneous tissue granulate without exposure tendon , bone , joint capsule . 5 . Subject 's wound free necrotic debris ( post debridement ) clinical infection , comprise healthy , vascular tissue . 6 . Subject 's AnkleBrachial Index ( ABI ) Doppler method ≥ 0.7 7 . The subject adequate circulation foot allow heal . This must demonstrate method describe section 5.1 8 . Subject 's diabetes control determine Investigator 9 . Study subject must reliable , responsible able visit clinic weekly full 16 week period . The subject willing able tolerate TCC . Subject willing comply monthly followup regimen 32 week ( 8 month ) The subject able return clinic ulcer recurrence occur 10 . Subject his/her legal representative read sign Institutional Review Board ( IRB ) approve Informed Consent form treatment 11 . No active malignancy except nonmelanoma skin cancer 1 . Subject clinical evidence gangrene part affect foot 2 . Subject Wagner type 3 great ulceration 3 . The subject 's ulcer due nondiabetic etiology , Ulcers arterial , venous stasis , pressure , radiation , traumatic , rheumatoid , vasculitis , collagen vascular disease , nondiabetic etiology 4 . Subject know sensitivity bovine porcine derive device 5 . Subject one medical condition ( ) include renal , hepatic , hematological , neurologic , immune disease opinion Investigator would make subject inappropriate candidate wound heal study 6 . Subject malignant disease ( cutaneous epithelioma ) remission 7 . Subject receive oral parenteral corticosteroid , immunosuppressive cytotoxic agent , anticipated require agent course study 8 . Subject chronic osteomyelitis determine high resolution ultrasonography 9 . Subject 's ulcer infect accompanied active cellulitis determine Investigator 10 . Subject condition ( ) seriously compromise subject 's ability complete study 11 . Subject pregnant lactating time treatment 12 . Subject receive growth factor therapy ( e.g . autologous plateletrich plasma gel , bacaplermin , bilayered cell therapy , dermal substitute , extracellular matrix ) within two week enrollment . If Santyl collagenase use , subject must washout period 2 week MatriStem® apply . 13 . Subject currently receive receive radiation chemotherapy within 3 month randomization 14 . Subject history alcohol drug abuse 15 . Subject allergic broad spectrum primary &amp; secondary dressing material , include occlusive dressing adhesives dressing . 16 . Subject currently enrol participate within previous 30 day enrollment another device , drug biological trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>